Related Experiment Video
Updated: Aug 15, 2025

Glycan Node Analysis: A Bottom-up Approach to Glycomics
Published on: May 22, 2016
O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma
Peng Zhou1, Wen-Yi Chang1, De-Ao Gong1
1Key Laboratory of Molecular Biology for Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Abstract:
Aberrantly elevated O-GlcNAcylation level is commonly observed in human cancer patients, and has been proposed as a potential therapeutic target. Speckle-type POZ protein (SPOP), an important substrate adaptor of cullin3-RING ubiquitin ligase, plays a key role in the initiation and development of various cancers. However, the regulatory mechanisms governing SPOP and its function during hepatocellular carcinoma (HCC) progression remain unclear. Here, we show that, in HCC, SPOP is highly O-GlcNAcylated by O-GlcNAc transferase (OGT) at Ser96. In normal liver cells, the SPOP protein mainly localizes in the cytoplasm and mediates the ubiquitination of the oncoprotein neurite outgrowth inhibitor-B (Nogo-B) (also known as reticulon 4 B) by recognizing its N-terminal SPOP-binding consensus (SBC) motifs. However, O-GlcNAcylation of SPOP at Ser96 increases the nuclear positioning of SPOP in hepatoma cells, alleviating the ubiquitination of the Nogo-B protein, thereby promoting HCC progression in vitro and in vivo. In addition, ablation of O-GlcNAcylation by an S96A mutation increased the cytoplasmic localization of SPOP, thereby inhibiting the Nogo-B/c-FLIP cascade and HCC progression. Our findings reveal a novel post-translational modification of SPOP and identify a novel SPOP substrate, Nogo-B, in HCC. Intervention with the hyper O-GlcNAcylation of SPOP may provide a novel strategy for HCC treatment.
Insights
Aberrantly elevated O-GlcNAcylation modifies Speckle-type POZ protein (SPOP), promoting hepatocellular carcinoma (HCC) by inhibiting Nogo-B ubiquitination. Targeting SPOP O-GlcNAcylation offers a potential HCC therapeutic strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Aberrant O-GlcNAcylation is linked to human cancers and presents a therapeutic target.
- Speckle-type POZ protein (SPOP) is crucial in cancer development, but its regulation in hepatocellular carcinoma (HCC) is unknown.
Purpose of the Study:
- To elucidate the regulatory mechanisms of SPOP in HCC progression.
- To identify novel post-translational modifications and substrates of SPOP in HCC.
Main Methods:
- Investigated SPOP O-GlcNAcylation at Ser96 by O-GlcNAc transferase (OGT) in HCC cells.
- Assessed SPOP localization, Nogo-B ubiquitination, and HCC progression in vitro and in vivo.
- Utilized S96A mutation to ablate O-GlcNAcylation and evaluate its effects.
Main Results:
- SPOP is O-GlcNAcylated by OGT at Ser96 in HCC.
- O-GlcNAcylation promotes SPOP nuclear localization, reduces Nogo-B ubiquitination, and drives HCC progression.
- Ablation of SPOP O-GlcNAcylation inhibits the Nogo-B/c-FLIP cascade and HCC progression.
Conclusions:
- Novel post-translational modification of SPOP by O-GlcNAcylation identified in HCC.
- Nogo-B identified as a novel SPOP substrate in HCC.
- Inhibiting SPOP hyper O-GlcNAcylation is a potential therapeutic strategy for HCC.
Related Concept Videos
Mutagenicity and Carcinogenicity
Induced Pluripotent Stem Cells
Somatic...
Protein Glycosylation
Glycosylation occurs in...
Proteoglycans
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Abnormal Proliferation

